LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Lapatinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1652 | 4168 | 0.3963 | 0.1097 |
| SK-BR-3 | Lapatinib | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1499 | 4168 | 0.3598 | 0.0436 |
| SK-BR-3 | Lapatinib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1555 | 4168 | 0.3734 | 0.0682 |
| SK-BR-3 | Lapatinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1574 | 4168 | 0.3780 | 0.0767 |
| SK-BR-3 | Lapatinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1669 | 4168 | 0.4005 | 0.1173 |
| SK-BR-3 | Lapatinib | 10 | uM | LJP6 | 72 | hr | 1401 | 1796 | 4168 | 0.4309 | 0.1684 |
| SK-BR-3 | Sirolimus | 0.04 | uM | LJP6 | 72 | hr | 1401 | 2753 | 4168 | 0.6604 | 0.5360 |
| SK-BR-3 | Sirolimus | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2685 | 4168 | 0.6442 | 0.5119 |
| SK-BR-3 | Sirolimus | 0.37 | uM | LJP6 | 72 | hr | 1401 | 2786 | 4168 | 0.6681 | 0.5471 |
| SK-BR-3 | Sirolimus | 1.11 | uM | LJP6 | 72 | hr | 1401 | 2635 | 4168 | 0.6321 | 0.4938 |
| SK-BR-3 | Sirolimus | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2546 | 4168 | 0.6104 | 0.4602 |
| SK-BR-3 | Sirolimus | 10 | uM | LJP6 | 72 | hr | 1401 | 2532 | 4168 | 0.6072 | 0.4554 |
| SK-BR-3 | ZSTK474 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3262 | 4168 | 0.7821 | 0.7091 |
| SK-BR-3 | ZSTK474 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 2371 | 4168 | 0.5690 | 0.3973 |
| SK-BR-3 | ZSTK474 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1958 | 4168 | 0.4696 | 0.2362 |
| SK-BR-3 | ZSTK474 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1708 | 4168 | 0.4100 | 0.1342 |
| SK-BR-3 | ZSTK474 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1645 | 4168 | 0.3949 | 0.1075 |
| SK-BR-3 | ZSTK474 | 10 | uM | LJP6 | 72 | hr | 1401 | 1564 | 4168 | 0.3751 | 0.0716 |
| SK-BR-3 | BX-912 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3599 | 4245 | 0.8492 | 0.8063 |
| SK-BR-3 | BX-912 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3127 | 4245 | 0.7368 | 0.6514 |
| SK-BR-3 | BX-912 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 1423 | 4245 | 0.3362 | 0.0096 |
| SK-BR-3 | BX-912 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1438 | 4245 | 0.3393 | 0.0155 |
| SK-BR-3 | BX-912 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1423 | 4245 | 0.3361 | 0.0095 |
| SK-BR-3 | BX-912 | 10 | uM | LJP5 | 72 | hr | 1401 | 1404 | 4245 | 0.3316 | 0.0009 |
| SK-BR-3 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4622 | 4168 | 1.1095 | 1.1372 |